EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Programmed Release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A Modification-Mediated Mitochondrial Fission

Boyue Huang, Liu Xie, Ming Ke, Yonghong Fan, Ju Tan, Jianhua Ran, Chuhong Zhu iD

ACS Applied Materials & Interfaces · 11.10.2023 · 15 (40) · 46583-46597

DOI: 10.1021/acsami.3c06318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 27.09.2023. Verfasst von Boyue Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, and Laboratory of Neuroscience and Tissue Engineering, Basic Medical College, Chongqing Medical University, Chongqing 400016, …. Hauptthemen laut MEDLINE: Methyltransferases, Mitochondrial Dynamics, Myocytes, Cardiac, Myocardial Infarction. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Chongqing, Education Department of Hunan Province, Chongqing Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

M6A modification is an RNA-important processing event mediated by methyltransferases METTL3 and METTL14 and the demethylases. M6A dynamic changes after myocardial infarction (MI), involved in the massive loss of cardiomyocytes due to hypoxia, as well as the recruitment and activation of myofibroblasts. Balanced mitochondrial fusion and fission are essential to maintain intracardiac homeostasis and reduce poststress myocardial remodeling. Double-layer programmed drug release microneedle (DPDMN) breaks the limitations of existing therapeutic interventions in one period or one type of cells, and multitargeted cellular combination has more potential in MI therapy. By employing hypoxia-ischemic and TGF-β1-induced fibrosis cell models, we found that METTL3-14 inhibition effectively decreased cardiomyocyte death through the reduction of mitochondrial fragmentation and inhibiting myofibrillar transformation. DPDMN treatment of MI in rat models showed improved cardiac function and decreased infarct size and fibrosis level, demonstrating its superior effectiveness. The DPDMN delivers METTL3 inhibitor swiftly in the early phase to rescue dying cardiomyocytes and slowly in the late phase to achieve long-term suppression of fibroblast over proliferation, collagen synthesis, and deposition. RIP assay and mechanistic investigation confirmed that METTL3 inhibition reduced the translation efficiency of Drp1 mRNA by 5'UTR m6A modification, thus decreasing the Drp1 protein level and mitochondrial fragment after hypoxic-ischemic injury. This project investigated the efficacy of DPDMNs-loaded METTL3 inhibitor in MI treatment and the downstream signaling pathway proteins, providing an experimental foundation for the translation of the utility, safety, and versatility of microneedle drug delivery for MI into clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethyltransferasesMitochondrial DynamicsMyocytes, CardiacMyocardial InfarctionDynaminsAnimalsRatsRats, Sprague-DawleyHumansMaleNeedles

Stichwörter der Autor:innen

Drp1METTL3microneedlemitochondrial fissionmyocardial infarction

Substanzen

MethyltransferasesDynaminsDnm1l protein, rat

Autor:innen und Institutionen

  • Department of Anatomy, and Laboratory of Neuroscience and Tissue Engineering, Basic Medical College, Chongqing Medical University, Chongqing 400016, China.
  • Department of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing…
  • Department of Pathology and Pathophysiology, Hunan Medical College, Huaihua 418000, China.
  • Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing 400038, China.
  • Burn and Combined Injury, State Key Laboratory of Trauma, Chongqing 400038, China.

ORCID-Profile: Chuhong Zhu

Förderung

  • Natural Science Foundation of Chongqing
  • Education Department of Hunan Province
  • Chongqing Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Chongqing Key Laboratory for the Development and Utilization of Precious Medicinal Materials in the Three Gorges Reservoir Area of Chongqing Municipality
  • Outstanding Scientist Project of Chongqing

Zitieren

APA

Huang, B., Xie, L., Ke, M., Fan, Y., Tan, J., Ran, J., & Zhu, C. (2023). Programmed Release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A Modification-Mediated Mitochondrial Fission. ACS Applied Materials & Interfaces, 15(40), 46583-46597. https://doi.org/10.1021/acsami.3c06318

Vancouver

Huang B, Xie L, Ke M, Fan Y, Tan J, Ran J, et al. Programmed Release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A Modification-Mediated Mitochondrial Fission. ACS Applied Materials & Interfaces. 2023;15(40):46583-46597. doi:10.1021/acsami.3c06318

BibTeX
@article{Huang2023,
  author = {Huang, Boyue and Xie, Liu and Ke, Ming and Fan, Yonghong and Tan, Ju and Ran, Jianhua and Zhu, Chuhong},
  title = {Programmed Release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A Modification-Mediated Mitochondrial Fission},
  journal = {ACS Applied Materials & Interfaces},
  year = {2023},
  volume = {15},
  number = {40},
  pages = {46583--46597},
  doi = {10.1021/acsami.3c06318}
}
Kostenlos starten →